Peramivir injection in the treatment of acute influenza: a review of the literature

Ashley Wester\textsuperscript{1}  
Avinash K Shetty\textsuperscript{2}

\textsuperscript{1}Department of Pharmacy, \textsuperscript{2}Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA

\textbf{Abstract:} Influenza virus infection is a major cause of morbidity and mortality in children and adults globally. Seasonal epidemics are common due to the rapid virus evolution, whereas the frequent emergence of antigenic variants can result in pandemics and sporadic/endemic avian influenza virus infections. Although annual vaccination is the mainstay for influenza prevention and control, the use of antiviral agents must be considered for treatment and prophylaxis against influenza. Currently available antiviral drugs include neuraminidase inhibitors (NAIs), adamantanes, and a novel polymerase inhibitor (favipiravir). Peramivir is a recently US Food and Drug Administration-approved NAI for the treatment of acute uncomplicated influenza in adults. The chemical structure of peramivir allows it to bind to the influenza neuraminidase with much higher affinity than oseltamivir. Peramivir is effective against a variety of influenza A and B subtypes and has a lower half-maximal inhibitory concentration compared to other NAIs in vitro studies. Peramivir can be administered intravenously, a route that is favorable for hospitalized, critically ill patients with influenza. The long half-life of peramivir allows for once-daily dosing. The drug is eliminated primarily by the kidneys, warranting dose adjustments in patients with renal dysfunction. Studies have assessed the clinical efficacy of peramivir for treatment of pandemic influenza A (H1N1). Although anecdotal evidence supports the use of peramivir in pediatric patients, pregnant women, and hospitalized patients with severe influenza receiving continuous renal replacement therapy and extracorporeal membrane oxygenation, well-designed, controlled clinical trials should be conducted in order to assess its clinical efficacy in these patient populations.

\textbf{Keywords:} peramivir, influenza, pharmacokinetics, safety, efficacy, review

\textbf{Introduction}

The influenza virus causes a highly infectious, acute respiratory illness that causes significant morbidity and mortality in children and adults both in the US as well as globally.\textsuperscript{1} Seasonal influenza affects between 5\% and 20\% of the population in the US annually, resulting in 25–50 million cases each year.\textsuperscript{1} This significant number of influenza cases leads to approximately 225,000 hospitalizations and is responsible for 36,000 deaths each year in the US alone.\textsuperscript{2} Globally, the WHO (World Health Organization) estimates that up to 20\% of the population is infected with influenza each year, causing up to one billion infections, three-to-five-million cases of severe disease, and up to 300,000–500,000 deaths.\textsuperscript{3} Although endemics and pandemics of influenza have been surfacing for centuries, the pandemic influenza A (H1N1) that arose in the spring of 2009 was particularly devastating. The 2009 H1N1 virus infected individuals in almost
all countries globally and was responsible for 60.8 million cases, 273,304 hospitalizations, and 12,469 deaths, many of which were documented in pregnant women, indigenous populations, and in patients who were morbidly obese or had serious comorbidities.4,5

Despite the fact that the H1N1 pandemic revealed the need for better pandemic planning, it also illustrated the need for more effective antiviral agents for the treatment of severe influenza.6,7 In 2009, available therapies for acute influenza treatment included the adamantanes or M2 channel inhibitors and neuraminidase inhibitors (NAIs). M2 channel inhibitors include amantadine and rimantidine and have activity only against influenza A; however, the circulating H1N1 viruses were resistant to adamantanes and not recommended for treatment of influenza in the US.6,8 NAIs included oseltamivir (Tamiflu®; Genentech USA, Inc., South San Francisco, CA, USA) and zanamivir (Relenza®; GlaxoSmithKline, Brentford, UK), which have activity against both influenza A and B virus.6,8 Due to the fact that oseltamivir is administered orally and zanamivir is administered via the inhalation route, an unmet need for an intravenous (IV) antiviral agent existed for patients with severe influenza who were mechanically ventilated or critically ill.8 Peramivir (Rapivab™; BioCryst Pharmaceuticals, Inc., Durham, NC, USA), an investigational NAI that was in advanced clinical development during the pandemic of 2009, is an IV NAI that was a promising therapy for patients with contraindications or poor response to available antivirals.8,9 Peramivir binds tightly to the neuraminidase (NA) enzyme compared to other NAIs and inhibits the growth of influenza A and B virus in vitro.10

Due to the favorable route of administration and promising Phase II trials, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for this drug on October 23, 2009.8,9 Hospitalized patients were eligible for peramivir treatment if they were unresponsive to or were unable to tolerate available antivirals, or if oral and inhaled drug delivery routes were deemed unreliable.8 Under the EUA, health care providers were required to monitor and report medication errors, adverse events (AEs), and deaths to the FDA Adverse Event Reporting System.9

From the date of the EUA issuance through June 23, 2010, 1,371 requests for peramivir were submitted to the Centers for Disease Control and Prevention (CDC), and 2,129 5-day adult treatment courses were delivered to 563 hospitals.8 Following a survey of health care providers, 1,274 patients had received at least one dose of peramivir.8 The median age of peramivir recipients was 43 years (range, 0–92 years); 49% of patients were male.8 The Adverse Event Reporting System reports were completed for 344 patients and included 28 children and 3 pregnant women; 41% of patients for whom reports were received were critically ill and on mechanical ventilation, and 19% were on renal replacement therapies.9

Serious AEs reported included death (15%), H1N1 influenza (8%), respiratory failure (8%), acute renal failure (7%), and acute respiratory distress syndrome (7%); additionally, six medication errors were reported.9 Most patients who died during or following peramivir therapy were obese, immunosuppressed, >65 years, or had also received oseltamivir.8 The only treatment-emergent AE that was reported and found to be attributable to peramivir was development of rash.9 Other reports of AEs with peramivir use were confounded by severity of influenza disease, comorbidities, and concomitant medications.9 Following the evaluation of reported AEs during the EUA, it was concluded that many of the patients who suffered AEs were critically ill and therefore at risk of developing complications that may or may not be attributable to the drug use itself.9 Peramivir has been the subject of several excellent reviews.10–12

Peramivir has been approved for influenza treatment in both Japan and South Korea since 2010. In December 2014, peramivir was approved by the FDA for the treatment of acute, uncomplicated influenza in adults who have been symptomatic for ≤2 days.13 This review will outline the new literature that has been published in recent years so as to provide a better understanding of peramivir’s mechanism of action, pharmacology, clinical efficacy, safety, and tolerability, as well as its current place in influenza therapy.

**Microbiology overview and pharmacology of peramivir**

**Structure and mechanism of action**

Peramivir, like other NAIs, binds to the active site of the influenza virus NA enzyme in order to prevent spread of infectious virions. Two glycoproteins are important to facilitate the influenza virus to infect host cells, the aforementioned NA, as well as hemagglutinin. The hemagglutinin protein allows viral entry, while NA promotes release of the virus from infected host cells so as to continue to spread the infection.14 When peramivir binds to the active NA site on the virus, it is able to mimic the sialic acid residues present in the viral membrane to compete with neuraminic acid binding, which in turn prevents virion release.7,15–18

The peramivir molecule (Figure 1) contains a carboxylate group, a guanidino group, and lipophilic side chains off the cyclopentane backbone.19 Its empirical formula is $\text{C}_{13}\text{H}_{34}\text{N}_{4}\text{O}_{4}\cdot3\text{H}_{2}\text{O}$, with a molecular weight of 328.45 g/mol. The chemical structure of peramivir allows it to bind to the
influenza NA with much higher affinity than oseltamivir carboxylate, despite the similar structure in the cyclopentane backbone of the two drugs.\textsuperscript{20,21} The interaction between the NA arginine residue at position 292 and the carboxylic acid groups on zanamivir and oseltamivir allow binding of the drugs to the influenza NA. Additionally, the glutamic acid residue at position 119 in the NA enzyme interacts with the basic structures of zanamivir (guanidinium) and oseltamivir (amine) and allows for the difference in drug resistance profiles.\textsuperscript{19,20,22,23} Peramivir’s negatively charged carboxylate group allows for hydrogen bonding, while the acetamido group binds to the NA’s hydrophobic pocket. Strong hydrogen bonds and electrostatic interactions are also formed between the peramivir’s positively charged guanidinium group and the carboxylates of the NA.\textsuperscript{19,20,22,23} Due to these structural characteristics, the peramivir molecule has the ability to bind to the N9 site of the NA for a prolonged period of time (about 24 hours) with a slow dissociation rate.\textsuperscript{20,23}

**Pharmacokinetics**

The pharmacokinetic (PK) parameters of peramivir are outlined in Table 1.\textsuperscript{24} Oral administration of peramivir was assessed in a Phase III clinical trial, but was not found to achieve statistical significance in the treatment group.\textsuperscript{25} Subsequently, it was found to have very low bioavailability (<3%), which led to the development and assessment of parenteral formulations.\textsuperscript{23} Several Phase I clinical trials\textsuperscript{24} have been conducted to assess the PK parameters of both intramuscular (IM) and IV administration of peramivir in healthy adults, which have shown a linear relationship between the dose and maximum serum concentration ($C_{\text{max}}$) as well as area under the curve (AUC).\textsuperscript{24} Additionally, single-dose injections of IV and IM peramivir have been found to be bioequivalent. A Phase I, two-period crossover study was conducted in healthy volunteers, which found that peramivir administered via the IV and IM route to the same subjects at doses of 75 to 600 mg led to bioequivalence of the two routes when AUC was compared. Researchers also determined that the absolute bioavailability of IM peramivir ranged from 92% to 100% and that overall drug administration was safe and well tolerated.\textsuperscript{26}

Matsuo et al\textsuperscript{27} conducted a recent study of population PK in both healthy volunteers and influenza patients to assess factors that influence the PK parameters of peramivir. The study utilized 3,199 plasma concentration samples from 332 subjects that were analyzed from six trials conducted in Japan and the US. Subjects included healthy patients, patients with influenza, and patients with renal impairment. Researchers found that the plasma concentrations of peramivir were well described by a three-compartment model. Additionally, they determined that the most important factor influencing peramivir PK was creatinine clearance ($\text{CL}_{\text{CR}}$), owing to the fact that peramivir is primarily renally excreted. Age was also found to be related to peramivir clearance, while body weight was a factor in the volume of distribution of the drug, primarily when it came to the central compartment of the model. There were no differences between the Japanese or US subjects, and sex was also found to have no effects on peramivir PK. The study also utilized Monte Carlo simulations to determine that patients with a $\text{CL}_{\text{CR}}>50$ mL/min required no dose adjustment, while patients with a $\text{CL}_{\text{CR}}$ of 30–50 mL/min should have a 1/3-fold dose adjustment, and those with $\text{CL}_{\text{CR}}$ 10–30 mL/min should have a 1/6-fold dose adjustment in order to achieve AUCs comparable to patients with normal renal function.\textsuperscript{22} Studies have also been conducted to assess PK parameters of peramivir following single doses of the drug in both healthy and infected patients.

Zhang et al\textsuperscript{28} explored the PK profile of peramivir in healthy Chinese subjects through an open-label, randomized, single-dose, crossover study. They utilized doses of 300 and 600 mg, both given intravenously, and collected blood and urine samples at 17 designated time points and seven

![Chemical structure of peramivir.](image-url)
designated time intervals for up to 36 hours postdose. They found that the drug displays linear PKs at the tested doses and noted increases in $C_{\text{max}}$ and AUC in proportion to the dose given. Sato et al assessed 28 pediatric patients who were treated with 10 mg/kg of IV peramivir to determine the predictive peramivir concentration–time curve against the viruses with decreased susceptibility to NAIs. They found that peramivir concentration decreased to $<0.1\%$ of the $C_{\text{max}}$ at 24 hours postadministration. They concluded that peramivir readministration should be considered in the event of lack of clinical improvement in patients with normal susceptibility to influenza A and B and that better viral inhibition and lower frequency of adverse effects may be expected with divided administration.

To date, no clinical trials have been specifically conducted to assess the PK parameters of peramivir in patients undergoing continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO). Case reports of peramivir use in patients on CRRT have shown that peramivir has high clearance by various forms of CRRT, including continuous venovenous hemofiltration. A recent report by Bentley et al assessed the PK parameters of a 29-year-old female receiving peramivir during continuous venovenous hemofiltration, which were consistent with those of previous reports. The dialysate flow rate was 16.7 mL/min, producing a total ultrafiltrate of 14.2 mL/min. They obtained both pre- and postfilter peramivir samples from blood and effluent at 4.5 and 8.5 hours following the third dose of 480 mg of peramivir, as well as plasma concentrations at several time points for measurement of AUC. Researchers found the $C_{\text{max}}$ at 30 minutes to be 19,477 ng/mL, $C_{\text{min}}$ to be 2,750 ng/mL, and AUC to be 196,166 ng·h/mL. The plasma half-life was estimated to be 8.2 hours, and researchers noted a log-linear decrease over the 24-hour period. Thus, peramivir was found to have significant clearance with continuous venovenous hemodiafiltration with a calculated saturation coefficient of 0.98, which was very close to the estimated saturation coefficient of 1. Additionally, Tang et al describe the successful use of peramivir in a patient with acute respiratory distress syndrome caused by the influenza A virus H7N9 who underwent continuous venovenous hemodiafiltration in addition to venovenous ECMO. Though they do not report PK parameters in their patient, they do describe that they were able to remove her from venovenous ECMO support after 13 days. Dedicated studies of peramivir use in advanced forms of life support as well as in CRRT will provide valuable information for clinicians who desire to use peramivir in their clinical practice with critically ill patients.

### Spectrum of antivirus activity

Peramivir has activity against both influenza A and influenza B viruses as demonstrated by both in vivo and in vitro studies. The potent antiviral effects of the drug confer activity against pandemic and highly pathogenic strains of influenza subtypes H5N1 and H9N2. Additionally, peramivir has the ability to inhibit the replication of nine different types of avian influenza viruses. In an experimental mouse model of H7N9 avian influenza virus infection, repeated doses of peramivir at 30 mg/kg body weight demonstrated antiviral activity resulting in the resolution of clinical signs, improved survival, and prevention of recurrence of neurological symptoms.

Recent studies have been conducted on isolates of previous influenza seasons to determine the susceptibility of the viruses to NAIs. Table 2 outlines the susceptibility profiles of these viruses as evaluated by two studies conducted by Dapat et al and Leang et al. Dapat et al assessed the susceptibility of influenza virus isolates during the 2009–2010 and 2010–2011 seasons in Japan and showed that type A influenza

### Table 2 In vitro neuraminidase inhibitor activity against influenza A and B viruses

<table>
<thead>
<tr>
<th>Study</th>
<th>Virus</th>
<th>Duration</th>
<th>N</th>
<th>Oseltamivir IC$_{50}$ (nM)</th>
<th>Zanamivir IC$_{50}$ (nM)</th>
<th>Peramivir IC$_{50}$ (nM)</th>
<th>Laminamivir IC$_{50}$ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Range</td>
<td>Mean±SD</td>
<td>Range</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>Dapat et al$^{14}$</td>
<td>A(H1N1) pdm09</td>
<td>2009–2010</td>
<td>57</td>
<td>1.48–10.91</td>
<td>1.88±0.25</td>
<td>0.49–1.92</td>
<td>0.69±0.09</td>
</tr>
<tr>
<td></td>
<td>A(H1N1) pdm09</td>
<td>2010–2011</td>
<td>60</td>
<td>0.72–443.95</td>
<td>1.37±0.31</td>
<td>0.30–1.79</td>
<td>0.63±0.14</td>
</tr>
<tr>
<td></td>
<td>A(H3N2) B</td>
<td>2010–2011</td>
<td>59</td>
<td>0.46–2.12</td>
<td>0.73±0.20</td>
<td>0.41–2.66</td>
<td>0.63±0.17</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16.97–59.12</td>
<td>27.09±11</td>
<td>29.33–92.3</td>
<td>53.74±17.25</td>
</tr>
<tr>
<td>Leang et al$^{15}$</td>
<td>A(H1N1) pdm09</td>
<td>2009–2012</td>
<td>580</td>
<td>0.17±0.10</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>A(H3N2) B</td>
<td>2009–2012</td>
<td>1,49</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Note:** Data from previous studies.$^{14,15}$

**Abbreviations:** IC$_{50}$ half-maximal inhibitory concentration; SD, standard deviation.
isolates were more susceptible to the NAIs in comparison to type B isolates. They noted that the half-maximal inhibitory concentration (IC₅₀) values for peramivir and laninamivir were significantly lower than those for oseltamivir and zanamivir, signifying a higher in vitro susceptibility of the viruses to peramivir and laninamivir. Researchers also examined eight A(H1N1)pdm09 viruses and one type B virus from patients following treatment with NAIs. The authors determined that there was an increase in prevalence of the H274Y mutation in the influenza A(H1N1)pdm09 from the 2009–2010 season to the 2010–2011 season and that patients with this mutation were resistant to treatment with oseltamivir and peramivir but retained susceptibility to zanamivir and laninamivir. Despite the discovery of other mutations in the isolated viruses and the widespread use of NAIs, researchers concluded that the prevalence of NAI-resistant influenza viruses in Japan remains low.₃₄

Leang et al.³⁵ collected influenza viruses from 19 countries in Asia, Africa, and Oceania between 2009 and 2012 to evaluate their susceptibility to peramivir and laninamivir. In addition to the IC₅₀ values recorded in Table 2 for viruses with normal inhibition, researchers determined that 19 of the total 599 A(H1N1)pdm09 viruses had highly reduced peramivir inhibition due to H275Y NA substitution upon genetic evaluation. Despite this increase in H275Y variants, the authors concluded that there were no marked changes in the frequency of peramivir-resistant variants despite the widespread use of NAIs.³⁵ Both these studies highlight the necessity for continuous susceptibility monitoring to determine if the viruses are developing resistance to these new NAIs.

Development of antiviral resistance
Emerging resistance of influenza viruses to antiviral agents, including the NAIs, is becoming an important public health concern for clinicians. Treatment options are affected by circulating resistant strains of the influenza virus and put patients at risk for treatment failure. Due to structural differences involving the chemical moieties involved in NA binding among the available NAIs, influenza resistance has been shown to be agent-specific.³⁶ Despite this, research by the WHO shows that influenza viruses in the Western Pacific, the Americas, and Europe have developed highly reduced inhibition to at least one of the four NAIs.³⁷

One of the most well-studied mutations that confers resistance among influenza viruses is the H275Y substitution in the NA protein. Mutations of this substitution have been found to confer a 400-fold decrease in susceptibility to oseltamivir and 140-fold decrease in susceptibility to peramivir in comparison to wild-type viruses.³⁸ Two case reports by Memoli et al.³⁹ demonstrate the ability of wild-type influenza viruses to develop mutations during therapy, specifically in immunocompromised hosts. One patient with a history of myelodysplastic syndrome and stem cell transplantation was treated with oseltamivir for influenza A infection for an extended period of time. Upon analysis of viral isolates throughout her treatment course, it was found that the initial wild-type virus had acquired an H275Y mutation by day 9 of oseltamivir therapy. Similarly, in a second patient, an H275Y mutation that resulted in significant reduction in viral susceptibility was recovered after 14 days of treatment with oseltamivir.³⁹ While development of NA substitutions has been specifically noted in patients who have received treatment with NAIs, Takashita et al.⁴⁰ have also identified patients with H275Y mutations that have never received prior treatment with NAIs. Six viruses in Japan were isolated in November and December of 2013, and though no epidemiological link was identified between the viruses, they were found to be closely genetically related. This finding suggests spread of a single resistant virus.⁴⁰

A CDC analysis of 87 specimens from 58 patients utilized pyrosequencing to determine that H275Y mutations were present in 38% of isolates from the 2009 influenza pandemic. In isolates that exhibited the H275Y variant at ≥50%, resistance to oseltamivir and peramivir was detected, though full susceptibility to zanamivir was retained. Additional substitutions were recovered from two patients, I223K or I22KR substitutions, and were found to have 38–52-fold enhancement in susceptibility to oseltamivir and 33–97-fold enhancement to peramivir.⁴¹

Takashita et al.⁴² aimed to monitor the emergence of NAI-resistant viruses in four influenza seasons from 2008 to 2012. Using allelic discrimination, gene sequencing, and susceptibility profiles, researchers determined that the detection rate of resistant viruses had increased from 1% in the 2009 pandemic season to 2% in the postpandemic period. They also found that 1.3% of over 12,000 A(H1N1)pdm09 isolates had acquired an H275Y substitution and that, in general, patients who were between 0 and 9 years had the highest detection rate for resistant viruses.⁴² A report of community transmission of oseltamivir-resistant A(H1N1) pdm09 in Australia advocates for rapid analysis of potentially transmissible virus strains. Twenty-nine viruses analyzed contained H275Y substitutions, and upon hemagglutinin and NA sequence analysis, it was determined that the strains were closely genetically related and likely accounted for the spread of a single variant.⁴²
Other mutations are less common but have been associated with reduced susceptibility to NAIs. A report of an A(H3N2) virus, A/Ohio/88/2012, was found to contain two rare substitutions, S245N and S247P. Researchers found that there was a 31-fold reduction in oseltamivir susceptibility and 66-fold reduction in peramivir susceptibility, which was mostly due to the SN247P mutation. Additionally, highly reduced inhibition was demonstrated in an A(H3N2) virus with an NA E119V mutation, a B/Yamagata-lineage with an H273Y mutation, as well as a B/Victoria-lineage strain with an NA E117G mutation. Overall, the concern for development of viral resistance to the currently available NAIs is justified and suggests that continued research be done to determine ways to decrease the spread of resistant influenza strains.

Clinical efficacy and comparative trials of peramivir

A compilation of randomized controlled trials of IV and IM peramivir in adult patients is provided in Table 3. Additional clinical trials, including open-label randomized trials as well as retrospective observational studies, are provided in Table 4.

Clinical trials of ambulatory patients with influenza

Two multicenter, phase II, randomized, double-blind, placebo-controlled trials were conducted by BioCryst Pharmaceuticals, Inc. in adult patients with positive rapid antigen tests (RATs) for influenza. The first study assessed 344 subjects who were randomized to receive a single dose of peramivir 150 mg IM, peramivir 300 mg IM, or placebo within 48 hours of symptom onset. The study found no statistically significant differences between treatment groups for the primary end point, time to alleviation of symptoms. The second study evaluated peramivir 600 mg IM as a single dose versus placebo, also in adult patients with symptom duration of <48 hours. From the 334 patients who completed the efficacy analysis, researchers concluded that there were no statistically significant differences between treatment groups for time to alleviation of symptoms. In general, these studies found that peramivir was safe and well tolerated.

In 2010, Kohno et al conducted an additional multicenter, phase II, randomized, double-blind, placebo-controlled trial in adult patients aged 20–64 years with influenza diagnosed by RATs. Subjects received peramivir 300 mg or 600 mg as a single IV dose or placebo within 48 hours of symptom onset. The primary end point was time to symptom alleviation, and 296 patients were included in the efficacy analysis. Statistically significant differences were found for both doses of peramivir compared to placebo, with a hazard ratio of 0.681 (P=0.0092) for the peramivir 300 mg group and 0.666 (P=0.0092) for the peramivir 600 mg group. This corresponded to a median time to symptom alleviation of 59.1 and 59.9 hours in the 300 and 600 mg peramivir groups, respectively, compared to 82 hours in the placebo group. To assess the time to symptom alleviation in ambulatory patients with high-risk influenza symptoms, Kohno et al then conducted a phase III, randomized, double-blind, uncontrolled study in which patients received peramivir 300 mg IV or peramivir 600 mg IV for 1–5 days. Thirty-seven patients were included, and the study determined that the median time to symptom alleviation was 68.6 hours in all patients. Researchers found that the 600 mg peramivir group had a significantly shorter duration of illness compared to the 300 mg group. Additionally, they determined that multiple doses of peramivir conferred more rapid symptom alleviation than single doses of peramivir.

Kohno et al conducted a multicenter, phase III, randomized, double-blind, double-dummy trial in adult patients with acute uncomplicated influenza A or B diagnosed by RATs. Patients were randomized to receive peramivir IV at doses of 300 or 600 mg as a single dose or oral oseltamivir at a dose of 75 mg twice daily for 5 days. The study found that the 1,091 patients included in the efficacy analyses had similar time to alleviation of symptoms in all three treatment groups: 78 hours for the 300 mg peramivir group, 81 hours for the 600 mg peramivir group, and 81.8 hours for the oseltamivir group. Based on the hazard ratios of 0.946 (95% CI, 0.793–1.129) for the 300 mg peramivir group and 0.970 (95% CI, 0.814–1.157) for the 600 mg peramivir group, researchers concluded that both peramivir regimens were noninferior to the oseltamivir group.

Clinical trials of hospitalized patients with influenza

Ison et al conducted a multicenter, phase II trial in hospitalized patients with acute or potentially life-threatening influenza in which patients were randomized to receive peramivir 200 mg, peramivir 400 mg, or placebo intravenously for 5 days in combination with oseltamivir or oral placebo. Researchers found no significant differences in the time to clinical stability or time to resumption of normal activities between groups and similarly found no differences between changes in viral titers at 48 hours. Thus, they concluded that peramivir was noninferior to oseltamivir in this patient population and had no significant differences in dose response between peramivir groups.
Table 3 Clinical efficacy of peramivir: randomized controlled trials of IV or IM peramivir in adults

<table>
<thead>
<tr>
<th>Study</th>
<th>Location/sponsor/trial ID</th>
<th>Design</th>
<th>Population/sample size</th>
<th>Regimen</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambulatory patients with acute uncomplicated influenza (normal hosts)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biocryst</td>
<td>US/Canada/Biocryst NCT00419263</td>
<td>Phase II, randomized, double-blind, placebo-controlled, multicenter</td>
<td>Adults with positive rapid antigen test for influenza</td>
<td>Peramivir 150 mg, 300 mg, or placebo as IM single dose &lt;48 hours of symptom onset</td>
<td>Completed (n=344) No statistically significant differences between treatment groups for time to alleviation of symptoms (primary endpoint) Improvement over placebo was 22.9 hours with 150 mg dose (P=0.284) and 21.1 hours with the 300 mg dose (P=0.152)</td>
</tr>
<tr>
<td>Atiee et al</td>
<td>US, Australia, New Zealand, South Africa/Biocryst</td>
<td>Phase II, randomized, double-blind, placebo-controlled, multicenter</td>
<td>Adults with positive influenza A or B (by RAT) with symptom duration ≤48 hours</td>
<td>Peramivir 600 mg versus placebo as IM single dose</td>
<td>Completed (n=402, n=334 efficacy analyses) No statistically significant differences between treatment groups for time to alleviation of symptoms (primary endpoint) Median time to alleviation 91.1 hours for 600 mg IM injection of peramivir and 106.1 hours for placebo</td>
</tr>
<tr>
<td>Kohno et al</td>
<td>Japan/Shionogi/0722T0621</td>
<td>Phase II, randomized, double-blind, placebo-controlled, multicenter</td>
<td>Adults aged 20–64 years with influenza symptoms and positive influenza A or B (by RAT)</td>
<td>Peramivir 300 or 600 mg IV single dose versus placebo &lt;48 hours of onset of symptoms</td>
<td>Completed (n=300, n=296 efficacy analyses) Statistically significant difference for both doses of peramivir compared with placebo for time to symptom alleviation (HR, 0.681 [P=0.0092] in 300 mg group and 0.666 [P=0.0092] in the 600 mg group compared to placebo; adjusted P-value 0.0092 for both comparisons) The median time to alleviation of symptoms was 59.1 hours after 300 mg peramivir, 59.9 hours after 600 mg peramivir compared to 82 hours for placebo Peramivir generally safe and well tolerated</td>
</tr>
<tr>
<td>Kohno et al</td>
<td>Japan/Shionogi/0815T0631</td>
<td>Phase III, randomized, double-blind, double-dummy, controlled, multicenter</td>
<td>Adults aged ≥20 years with influenza symptoms and positive influenza A or B (by RAT)</td>
<td>Peramivir 300 mg or 600 mg IV single dose versus oral oseltamivir 75 mg BID ×5 days</td>
<td>Completed (n=1,093, n=1,091 efficacy analyses) Similar time to symptom alleviation (primary endpoint) for all three treatment groups (78 hours for 300 mg peramivir, 81 hours for 600 mg peramivir, and 81.8 hours for oseltamivir) The hazard ratios of the 300- and 600-mg groups compared to the oseltamivir group were 0.946 (97.5% CI, 0.793–1.129) and 0.970 (97.5% CI, 0.814–1.157), respectively Both peramivir groups were noninferior to the oseltamivir group (97.5% CI, &lt;1.170)</td>
</tr>
<tr>
<td>High-risk ambulatory patients with acute uncomplicated influenza</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kohno et al</td>
<td>Japan/Shionogi/0816T0632</td>
<td>Phase III, randomized, double-blind, uncontrolled, multicenter</td>
<td>High-risk patients with influenza symptoms and positive influenza A or B (by RAT)</td>
<td>Peramivir 300 or 600 mg IV ×1–5 days</td>
<td>Completed (n=37 efficacy analyses) The median time to symptom alleviation was 68.6 hours (90% CI, 41.5–113.4 hours) in all patients The duration of influenza illness was significantly shorter (hazard ratio, 0.497; 90% CI, 0.25–0.984) in the 600 mg group than in the 300 mg group Patients who received multiple doses of peramivir showed more rapid symptom alleviation compared to those who received single doses</td>
</tr>
</tbody>
</table>

(Continued)
A phase III, randomized, open-label study was conducted by the National Institutes of Health in hospitalized patients aged 14–92 years with confirmed or suspected H1N1 influenza.51 Patients received peramivir 300 mg IV twice daily or peramivir 600 mg IV once daily and were found to have similar reduction in influenza virus titers over the first 24 hours. An analysis of the intention-to-treat population revealed a median time to fever resolution of 25.3 hours, with time to clinical resolution of 92 hours, time to symptom alleviation of 145 hours, and time to resumption of usual activities of 26.8 days.51 An additional randomized, double-blind, controlled, phase III study was conducted by the National Institutes of Health to assess peramivir use in hospitalized adults and adolescents with influenza confirmed through RAT. Time to clinical resolution at day 5 was the primary outcome and was determined to be 42.5 hours for peramivir versus 49.5 hours for placebo (P=0.97). Due to these results, this study was terminated following a preplanned interim analysis.52

Additional studies have demonstrated the clinical effects of peramivir in adult patients.53,54 An open-label, randomized trial of hospitalized patients of ≥12 years of age was conducted by Ison et al54 to determine viral titer decline between two peramivir regimens. A total of 234 patients were randomized to receive either peramivir 300 mg IV twice daily (or 5 mg/kg twice daily for patients <18 years) or peramivir 600 mg IV twice daily for patients ≥18 years.54

Primary outcome: similar reduction in influenza virus titer in nucleoprotein samples over the first 48 hours for both groups (−1.66 [95% CI, −2.32 to −0.61] for 300 mg peramivir twice daily and −1.47 [95% CI, −1.89 to −0.75] for 600 mg peramivir once daily).

The analysis of the combined intention-to-treat population showed median time to resolution of fever was 25.3 hours; time to clinical resolution, 92 hours; time to alleviation of symptoms, 145 hours; and time to resumption of usual activities, 26.8 days.51

No significant differences in the time to clinical stability (primary end point) or time to resumption of normal activities and change in viral titers at 48 hours (secondary end points) between any of the treatment groups. Peramivir was non-inferior to oseltamivir in hospitalized patients with acute influenza and demonstrated similar tolerability.
Table 4 Other clinical studies of peramivir in influenza infection in adult and pediatric patients

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Population/sample size</th>
<th>Regimen</th>
<th>Results/conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yoshino et al&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Retrospective cohort</td>
<td>Adults &gt;18 years of age hospitalized from October 2012 to March 2013; n=32</td>
<td>Peramivir 300 mg IV once (or adjusted for renal dysfunction or severity) versus oral oseltamivir 75 mg BID for 5 days</td>
<td>n=23 in peramivir group, n=9 in oseltamivir group No difference between peramivir and oseltamivir groups for time to defervescence (30.9±18.7 hours versus 34.7±18.6 hours) or survival rate (95.7% versus 100%) respectively Concluded that the clinical efficacy of peramivir is noninferior to that of oseltamivir Viral titers declined similarly without difference between regimens; no significant differences in virologic endpoints between arms Peramivir was found to be safe and well tolerated</td>
</tr>
<tr>
<td>Ison et al&lt;sup&gt;34&lt;/sup&gt;</td>
<td>Open-label, randomized trial</td>
<td>Hospitalized patients ≥6 years of age; n=234</td>
<td>Peramivir 300 mg IV twice daily versus peramivir 600 mg IV once daily for adults ≥18 years or 5 mg/kg twice daily versus 10 mg/kg once daily for children and adolescents</td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sugaya et al&lt;sup&gt;35&lt;/sup&gt;</td>
<td>Multicenter, open-label, uncontrolled trial</td>
<td>Hospitalized children age ≥28 days to &lt;16 years with influenza infection during the 2009 pandemic A (H1N1) epidemic; n=106</td>
<td>Peramivir IV 10 mg/kg (max. 600 mg) once daily</td>
<td>Median time to alleviation of symptoms was 29.1 hours (95% CI, 22.1–32.4 hours) Concluded that peramivir is clinically and virologically effective and safe in children with pH1N1 virus infection</td>
</tr>
<tr>
<td>Shobugawa et al&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Observational trial</td>
<td>Outpatient pediatric patients; n=263; oseltamivir = 104, peramivir = 4; patients treated with peramivir were age 8.8±3.9 years</td>
<td>Peramivir IV 10 mg/kg (max. 600 mg) as a single dose; oseltamivir 150 mg per day divided BID for children &gt;37.5 kg or 4 mg/kg per day divided BID for children &lt;37.5 kg</td>
<td>Peramivir group had the fastest time to fever alleviation of all groups (median 17.0 hours; 95% CI, 7.2–26.8 hours); result was statistically significant compared to oseltamivir group (P=0.044)</td>
</tr>
<tr>
<td>Hikita et al&lt;sup&gt;37&lt;/sup&gt;</td>
<td>Retrospective chart review</td>
<td>Outpatient pediatric patients aged 0–18 years; total n=223 • influenza A patients aged 5–18 years: peramivir =15, laninamivir =1, zanamivir =18 • influenza B patients aged 5–18 years: peramivir =13, laninamivir =13, zanamivir =20</td>
<td>Peramivir IV 10 mg/kg (max. 300 mg) once daily</td>
<td>In influenza A patients aged 5–18 years, median fever duration with peramivir was shorter at 1 day compared to that of zanamivir at 2 days (P=0.0242) In influenza B patients aged 5–18 years, median fever duration was 3 days with laninamivir versus 1 day with peramivir (P=0.0097) Concluded that peramivir is very useful in pediatric influenza patients</td>
</tr>
<tr>
<td>Critically ill patients (adults and children)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sorbello et al&lt;sup&gt;38&lt;/sup&gt;</td>
<td>Retrospective chart review of adverse events reported during the EUA</td>
<td>Hospitalized patients aged &lt;1 to 90 years; n=344</td>
<td>Not described, median duration of peramivir was 5 days</td>
<td>The only treatment-emergent adverse event found to be attributable to peramivir was rash</td>
</tr>
<tr>
<td>Louie et al&lt;sup&gt;39&lt;/sup&gt;</td>
<td>Retrospective comparative analysis of critically ill patients who received peramivir versus critically ill patients treated with other neuraminidase inhibitors</td>
<td>Hospitalized patients with A(H1N1)pdm09 infection aged 5 months to 81 years; n=57 patients who received peramivir</td>
<td>Not described</td>
<td>Twenty-nine (51%) patients treated with peramivir died Fatal peramivir cases were more likely to have acute renal failure (P=0.02), shorter length of hospital stay (P=0.002), and shorter duration or peramivir (7 versus 9 days; P=0.02) compared to nonfatal cases Peramivir patients were more likely to die than non-peramivir patients (P&lt;0.0001), which could be due to the preexisting severity of disease prior to peramivir treatment</td>
</tr>
</tbody>
</table>

Abbreviations: BID, twice daily; CI, confidence interval; EUA, emergency use authorization; IV, intravenous.
once daily (or 10 mg/kg once daily for patients <18 years). The study found that viral titers declined similarly between the two regimens and that there were no significant differences in virologic end points between the arms. In general, peramivir was found to be both safe and well tolerated in both regimens.54

Observational studies of pediatric patients with influenza

While retrospective and uncontrolled trials have been emerging to assess the use of peramivir in pediatric patients in recent years, randomized controlled trials are yet to have been conducted in this patient population. A multicenter, open-label trial was conducted by Sugaya et al55 that evaluated patients ≥28 days old but <16 years old who were hospitalized during the 2009 H1N1 epidemic. Patients received peramivir 10 mg/kg IV at a maximum of 600 mg once daily. The median time to alleviation of symptoms was 29.1 hours, and the drug was found to be both clinically and virologically effective as well as safe in pediatric patients.55 An observational trial of pediatric outpatients was conducted to assess time to fever alleviation with use of various NAIs.56 Out of a total of 263 patients, four received peramivir as a single dose of 10 mg/kg (maximum of 600 mg). The peramivir group was found to have a median time to fever alleviation of 17 hours, which was the fastest of all the NAI groups and was found to be a statistically significant time difference when compared to the oseltamivir group \(P=0.044\).56

Hikita et al57 also conducted a retrospective chart review of pediatric outpatients and found that in patients aged 5–18 years with influenza A, the duration of fever with peramivir was shorter in comparison to patients treated with zanamivir. In patients with influenza B within the same age group, fever duration was found to be significantly shorter in patients treated with peramivir versus those treated with laninamivir \(P=0.0097\). Although a number of studies of peramivir use in children and adolescents has been reported, it is difficult to draw conclusions given small sample sizes or lack of information regarding number of patients treated with peramivir.58,59 Further studies should assess both the safety and efficacy of peramivir in children.

Retrospective studies of critically ill adults and children

In one retrospective comparative analysis, researchers evaluated hospitalized, critically ill patients aged 5 months to 81 years, of whom 57 received peramivir. They found that 51% of patients who received peramivir died, but that fatal peramivir cases were more likely to have developed acute renal failure, had a shorter length of hospital stay, and received a shorter course of peramivir as compared to patients who did not receive the drug. While patients who received peramivir were found to be more likely to die than those who did not receive it \(P<0.0001\), researchers hypothesized that this was likely due to the preexisting severity of the patient cases prior to receiving peramivir treatment itself, but also that more studies should be conducted to assess the safety of peramivir in the critically ill patient population.60

Antiviral combination therapy for severe influenza

The role of antiviral combinations and antiviral–immunomodulator combination therapy for severe influenza has been reviewed recently.61 Preclinical studies demonstrate a potential for combination therapy including NAIs (such as oseltamivir or IV zanamivir or IV peramivir as a foundation drug) in conjunction with antiviral agents with different mechanisms of action. No key PK interactions have been observed in healthy volunteers receiving IV peramivir and oral oseltamivir.62 Well-designed controlled clinical trials must be conducted to investigate the efficacy of novel combination therapies for severe influenza infections, especially those caused by novel viruses such as 2009 H1N1, avian influenza A H5N1, or the avian influenza A H7N9.61

Safety and tolerability in clinical use of peramivir

The most commonly reported AEs as well as the warnings and precautions as outlined in the package insert by BioCryst Pharmaceuticals are outlined in Table 5.63

Two studies assessing adverse events of peramivir were conducted by BioCryst Pharmaceuticals in hospitalized patients with influenza.64 BCX1812-301 was a randomized, double-blind, placebo-controlled trial that assessed the incidence of adverse effects in patients receiving peramivir 600 mg IV once daily for 5–10 days in addition to standard of care, which could include an additional NAI.64 A total of 398 patients were included in the study, 88 of whom received peramivir alone and 176 of whom received peramivir in addition to another NAI. Researchers determined that the incidence of adverse effects did not increase with the use of peramivir in addition to oseltamivir and that the incidence of AEs in patients receiving peramivir was similar to that of patients receiving standard of care alone. In this trial, the majority of adverse effects involved the gastrointestinal tract, laboratory parameters, or were infectious or respiratory in nature.64 The second trial, BCX1812-303, prohibited the
Peramivir for treatment of influenza

The use of concomitant NAIs and assessed the differences in adverse effects between a peramivir regimen of 600 mg IV daily versus peramivir 300 mg IV twice daily. The trial concluded that the incidence of adverse effects was similar between groups and that gastrointestinal side effects were seen most commonly.64

Komeda et al65,66 conducted postmarketing drug use investigations of peramivir in both adult and pediatric populations. Safety was assessed in 1,174 adult patients from October 2010 to February 2012, and it was determined that the incidence rate of adverse drug reactions (ADRs) was 4.34% (51/1,174). Diarrhea, vomiting, and nausea were the most frequently reported, with incidence rates of 1.87%, 0.85%, and 0.68%, respectively. No ADRs were reported as serious in this patient population, and 91% of ADRs arose within 3 days of peramivir administration, with 96.2% of them being resolved or improved within 7 days of onset. Safety was also assessed in 1,199 pediatric patients aged <15 years. Two hundred forty-five AEs were observed, corresponding to an incidence rate of 14.01% (168/1,199). ADRs accounted for 115 of these events, and commonly reported symptoms were diarrhea and abnormal behavior. Fourteen serious ADRs were observed among 12 patients and included five cases of abnormal behavior as well as five cases of decreased neutrophil count. The majority of events (87%) occurred within 3 days of peramivir initiation, and 87.8% had resolved or improved within 7 days of onset. Overall, these two studies concluded that peramivir is safe in both adult and pediatric populations.65,66

While peramivir has been found to be generally safe and effective in most patient populations, case reports have been published which demonstrate that rare adverse effects have occurred. Hayashi et al67 reported a case of a 73-year-old woman with myasthenia gravis who experienced acute respiratory failure and an exacerbation of myasthenia gravis following IV peramivir treatment for influenza A. Investigators reported a decrease in oxygen saturation and altered consciousness within 20 minutes of peramivir administration in this patient.68 Additionally, Harada-Shirado et al68 reported a case of severe immune thrombocytopenia in a 44-year-old male patient being treated with peramivir for influenza A infection. Bone marrow findings and peripheral blood examination were consistent with immune thrombocytopenia, and further testing revealed a drug-induced lymphocyte-stimulating test with positivity to peramivir.

**Patient-focused perspectives**

In general, peramivir has been found to be well tolerated by patients in clinical trials. Peramivir can be administered intravenously, a route that is favorable for hospitalized, critically ill patients with influenza. Since peramivir is a...
parenteral agent that requires IV or IM administration, it is most appropriate to administer in a clinic or in inpatient setting. Many patients who will be treated with full a course of peramivir are likely to be critically ill; therefore, adherence to the once-daily medication regimen will be overseen by the inpatient health care team. Widespread seasonal immunization and optimal use of antiviral agents including peramivir are key tools in our armamentarium against the influenza virus.

Data regarding drug interactions with peramivir are lacking. The manufacturer labeling recommends to avoid use of live attenuated influenza vaccine within 2 weeks before or 48 hours after peramivir administration due to the NAI’s ability to inhibit viral replication and therefore reduce vaccine efficacy. Since peramivir is not hepatically metabolized, the concern for cytochrome P450-mediated drug interactions is very low. In clinical trials, peramivir was not shown to have interactions with oral rimantadine, oseltamivir, oral contraceptives, or probenacid.$^61$

**Conclusion**

Peramivir is a recently FDA-approved NAI for the treatment of influenza A and B. As a parenteral agent, it can be given via IV administration, a route that may be favorable for the critically ill population, although studies have shown that enteral administration of standard doses of oseltamivir has adequate absorption with therapeutic blood levels in critically ill adult patients.$^69,70$ The long half-life of peramivir allows for once-daily dosing; however, due to elimination primarily by the kidneys, dose adjustments are required in patients with renal dysfunction. Peramivir has been shown to be efficacious against a variety of influenza A and B subtypes and has been found to have a lower IC$_{50}$ compared to other NAIs in in vitro studies. Several studies have been conducted to assess its clinical efficacy for treatment of A(H1N1)pdm09, and trials continue to be conducted to assess its utility in post-pandemic influenza. Studies of peramivir demonstrating an effect on hospitalizations or mortality are lacking. The efficacy of peramivir in hospitalized patients with severe influenza needs further investigation. Though case reports and retrospective studies support the use of peramivir in pediatric patients, pregnant women, and patients undergoing CRRT and ECMO, well-designed, controlled clinical trials should be conducted in order to assess its clinical efficacy in these patient populations.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


64. Dobo SM, Elder J, Collis P. Safety of peramivir in hospitalized influenza. Poster #1169 presented at: 53rd Annual Meeting of the Infectious Diseases Society of America; October 8–11; Philadelphia, PA.